(Q46958467)

26 December 2017

title

(-)Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells (English)

1 reference

26 December 2017

1 reference

1 reference

Yang Meng

1

1 reference

26 December 2017

Yan Li

2

1 reference

26 December 2017

Jing Li

3

1 reference

26 December 2017

Hongyan Li

4

1 reference

26 December 2017

Jianjiang Fu

5

1 reference

26 December 2017

Yue Liu

6

1 reference

26 December 2017

He Liu

7

1 reference

26 December 2017

Xiaoguang Chen

8

1 reference

26 December 2017

publication date

1 November 2007

1 reference

26 December 2017

published in

Leukemia & Lymphoma

1 reference

26 December 2017

volume

48

1 reference

26 December 2017

issue

11

1 reference

26 December 2017

page(s)

2204-2212

1 reference

26 December 2017

The biology of CML blast crisis

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583991

Imatinib mesylate--a new oral targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583991

Clinical decisions for chronic myeloid leukemia in the imatinib era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583991

An overview of the clinical pharmacology and therapeutic potential of gossypol as a male contraceptive agent and in gynaecological disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583991

Upregulation of Fas/Fas ligand-mediated apoptosis by gossypol in an immortalized human alveolar lung cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583991

Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583991

Involvement of reactive oxygen species-independent mitochondrial pathway in gossypol-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583991

Apoptosis and nitric oxide release induced by thalidomide, gossypol and dexamethasone in cultured human chronic myelogenous leukemic K-562 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583991

Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583991

Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583991

Apoptotic signaling pathways: caspases and stress-activated protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583991

Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583991

Molecular mechanisms of resistance of leukemia to imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583991

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583991

A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583991

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583991

Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583991

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583991

RETRACTED: Inactivation of MAP kinase signalling in Myc transformed cells and rescue by LiCl inhibition of GSK3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583991

Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583991

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583991

Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701583991

10.1080/10428190701583991

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

1 reference

26 December 2017